vaccine

Important COVID Vaccination Program Guidance – Vaccination of Children Ages 5-11

Important COVID Vaccination Program Guidance - Vaccination of Children Ages 5-11 Please see the attached Guidance for the New York State COVID-19 Vaccination Program: Vaccination of Children Ages 5-11; Information for Health Care Professionals about the Screening Checklist for the Administration of Pfizer-BioNTech COVID-19 Vaccine for Children 5-11 years old; and COVID-19 Immunization Screening and Consent Form: Children and Adolescents Ages

By admin|2022-09-21T19:50:45+00:00November 5th, 2021|Covid Resources|0 Comments

Important COVID Vaccination Program Guidance (Oct. 25, 2021)

Important COVID Vaccination Program Guidance (Oct. 25, 2021) The attached information was sent to all providers enrolled in the NYS COVID-19 vaccination program. It is updated to reflect the FDA authorization and CDC approval of Moderna and J&J booster doses for eligible individuals and the administration of heterologous booster doses. Included are: The attached Guidance for The

By admin|2022-09-21T19:50:10+00:00October 25th, 2021|Covid Resources|0 Comments

Recommendations for a single dose of the Pfizer-BioNTech COVID-19 Vaccine

Dear COVID-19 Vaccination Provider: On September 24, 2021, under the U.S. Food and Drug Administration’s (FDA) updated emergency use authorization (EUA), the CDC issued recommendations for a single dose of the Pfizer-BioNTech COVID-19 Vaccine at least six months after completion of the primary series for the following individuals: individuals 65 years of age and older, and

By admin|2022-09-21T19:49:43+00:00September 27th, 2021|Covid Resources|0 Comments

Pfizer-BioNTech COVID-19 Vaccine Licensure and Expiration Extension

Pfizer-BioNTech COVID-19 Vaccine Licensure and Expiration Extension Dear COVID-19 Vaccination Provider, The FDA granted full licensure for Pfizer's COVID-19 vaccine on August 23, 2021. The full licensure applies to the use of this vaccine in the 16+ population. The vaccine also continues to be available under emergency use authorization (EUA) for adolescents 12 through 15 years of age and

By admin|2022-09-21T19:49:06+00:00August 30th, 2021|Covid Resources|0 Comments

Janssen/Johnson & Johnson COVID-19 Vaccine Expiration Extension

Janssen/Johnson & Johnson COVID-19 Vaccine Expiration Extension On July 29, 2021, the U.S. Food & Drug Administration (FDA) authorized an extension of the shelf life for the Janssen/Johnson & Johnson (J&J) single-shot COVID-19 vaccine by 45 days, from 4.5 months to 6 months. The decision is based on data from ongoing stability assessment studies, which have

By admin|2022-09-21T19:48:23+00:00July 30th, 2021|Covid Resources|0 Comments

Important Information regarding Janssen/Johnson & Johnson (J&J) COVID-19 Vaccine

Important Information regarding Janssen/Johnson & Johnson (J&J) COVID-19 Vaccine On July 13, 2021, the U.S. Food and Drug Administration (FDA) announced revisions to the Emergency Use Authorization (EUA) fact sheets for the Janssen/Johnson & Johnson (J&J) COVID-19 vaccine to include information regarding an observed increased risk of Guillain-Barre Syndrome (GBS) after administration of the vaccine.

By admin|2022-09-21T19:47:25+00:00July 15th, 2021|Covid Resources|0 Comments

New York State Reaches 70 Percent Adult COVID-19 Immunization

For Immediate Release June 15, 2021 New York State Reaches 70 Percent Adult COVID-19 Immunization Governor’s Vaccine Distribution and Implementation Task Force Member and NYS Medical Society Immediate Past President Reflects on Reaching Important Milestone and Calls for Continued Vaccination Efforts Statement from Bonnie Litvack, MD Immediate Past President, Medical Society of the State of New

By admin|2022-09-21T19:42:12+00:00June 15th, 2021|Press Release, Special Announcements|0 Comments

JJ COVID Vaccine Extension

Important Information regarding Janssen/Johnson & Johnson (J&J) COVID-19 Vaccine On July 13, 2021, the U.S. Food and Drug Administration (FDA) announced revisions to the Emergency Use Authorization (EUA) fact sheets for the Janssen/Johnson & Johnson (J&J) COVID-19 vaccine to include information regarding an observed increased risk of Guillain-Barre Syndrome (GBS) after administration of the vaccine.

By admin|2022-09-21T19:46:06+00:00June 15th, 2021|Covid Resources|0 Comments

“Universal Dose” Administration Process

Dear Enrolled Provider: Effective today, May 11th, New York State is moving to a “Universal Dose” administration process for all multi-dose COVID-19 vaccine types. All doses are now considered universal doses, which means that doses can be used for a first dose or a second dose, irrespective as to whether they were originally shipped to providers as a first dose or a second dose. First and

By admin|2022-09-21T19:45:30+00:00May 11th, 2021|Covid Resources|0 Comments

NYS DOH Commissioner has released a statement regarding the Johnson & Johnson vaccine

NYS Department of Health Commissioner Dr. Howard Zucker released the following statement regarding the Johnson & Johnson vaccine: "Today the CDC and FDA issued a statement recommending a pause in the use of the Johnson & Johnson vaccine out of an abundance of caution. New York State will follow the CDC and FDA recommendation and pause the use

By admin|2022-09-21T19:45:11+00:00April 13th, 2021|Covid Resources|0 Comments

vaccine

About MSSNY

Hot Links

Featured Member Benefits